Английская Википедия:Cadila Pharmaceuticals
Шаблон:Short description Шаблон:Distinguish Шаблон:Use dmy dates Шаблон:Use Indian English Шаблон:Infobox company
Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.[1]
History
Cadila Laboratories
In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation.[2]
1995: Birth of Cadila Pharmaceuticals
The Modi and Patel families decided to split the business in 1995, two entities were formed - Cadila Pharmaceuticals Ltd (owned and controlled by Indravadan Modi and his son Rajiv Modi) and Cadila Healthcare (owned by Ramanbhai Patel and his son Pankaj Patel family).[2]
Operations
Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.[3]
Research
Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is staffed by 300 scientists.Шаблон:Citation needed
The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.[4]
Products and services
Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – 'Rabeloc'.[5] In 2009, the world's first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – 'Risorine'[6] and world's first drug combination for prevention of Cardiovascular Diseases – 'Polycap' were introduced by Cadila Pharmaceuticals.[7] For the patients with Non Small Cell Lung Cancer (NSCLC), the company introduced 'Mycidac-C' - first in the class active immunotherapy as well as drug targeting Desmocollin.[8] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac.Шаблон:Citation needed
Alliances
In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.[9]
Controversies
Company
In 2014, a cautionary notice appeared on the FDA website highlighting substantial manufacturing practice discrepancies discovered by inspectors in March at Cadila Pharmaceuticals' Ankleshwar facility in Gujarat.[10] This incident marked one among several Indian pharmaceutical companies receiving regulatory warnings from the FDA, indicating increased scrutiny on generic drugmakers.[11] A similar kind of notices were again issued in 2016[12] and 2019.[13]
Management
In 2018, the chairman of the company, Rajiv Modi, went through a widely publicized and contentious divorce with his wife, Monica, who comes from a prominent Mumbai-based business family of Garware. At that time, Modi transferred Шаблон:INRConvert to Monica, who relinquished her rights, while custody of their son was awarded to Modi.[14][15]
In December 2023, Gujarat Police complied with a Gujarat High Court order, initiating a case against Rajiv Modi.[16] The case involves accusations of rape, assault, and intentional insult by a Bulgarian woman employed as a flight attendant and personal assistant at the company. She reported multiple instances of sexual harassment from February to March 2023, stating that she was terminated in April 2023 after resisting Modi's alleged “illicit demands”.[17][18]
References
External links
- ↑ Шаблон:Cite web
- ↑ 2,0 2,1 Шаблон:Cite web
- ↑ Financial Express 28 January 2013
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- Английская Википедия
- Страницы с неработающими файловыми ссылками
- Pharmaceutical industry of Gujarat
- Pharmaceutical industry of India
- Pharmaceutical companies of Gujarat
- Companies based in Ahmedabad
- Pharmaceutical companies established in 1951
- Pharmaceutical companies of India
- Indian brands
- 1951 establishments in Bombay State
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии